This site is intended for healthcare professionals

EU approves new IV formulation of Ultomiris for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.- Alexion Pharma

Read time: 1 mins
Last updated:21st Nov 2020
Published:21st Nov 2020
Condition: Paroxysmal Nocturnal Haemoglobinuria
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest